Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven)

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 4, 2004, Pages 347-351

  Mullighan, Charles G ^a   Rischbieth, Amanda ^b   Duncan, Elizabeth M ^a   Lloyd, John V ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b Wakefield Hospital   (Australia)

Author keywords

Deficiency; Factor VII; Inhibitor; NovoSeven; Recombinant

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTIINFECTIVE AGENT; BLOOD CLOTTING FACTOR 7; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G; PROTEIN G; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SEPHAROSE; VITAMIN K GROUP;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY BYPASS SURGERY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; HUMAN; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

FACTOR VII; FACTOR VII DEFICIENCY; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN G; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 2942585598     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200406000-00010     Document Type: Article

References (23)

1. Slease RB, Schumacher HR. Deficiency of coagulation factors VII and XII in a patient with Hodgkin's disease. Arch Intern Med 1977; 137:1633-1635.
2. Campbell E, Sanal S, Mattson J, Walker L, Estry S, Mueller L, et al. Factor VII inhibitor. Am J Med 1980; 68:962-964.
3. Delmer A, Andreu G, Horellou MH, Lecompte T, Samama M, Zittoun R. Acquired factor VII inhibitor: treatment using high-dose immunoglobulins, corticotherapy and plasma exchange. Ann Med Interne (Paris) 1988; 139(suppl 1):48-50.
4. Ndimbie OK, Raman BK, Saeed SM. Lupus anticoagulant associated with specific inhibition of factor VII in a patient with AIDS. Am J Clin Pathol 1989; 91:491-493.
5. Delmer A, Horellou MH, Andreu G, Lecompte T, Rossi F, Kazatchkine MD, et al. Life-threatening intracranial bleeding associated with the presence of an antifactor VII autoantibody. Blood 1989; 74:229-232.
6. Weisdorf D, Hasegawa D, Fair DS. Acquired factor VII deficiency associated with aplastic anaemia: correction with bone marrow transplantation. Br J Haematol 1989; 71:409-413.
7. Mehta J, Singhal S, Mehta BC. Factor VII inhibitor. J Assoc Physicians India 1992; 40:44.
8. de Raucourt E, Dumont MD, Tourani JM, Hubsch JP, Riquet M, Fischer AM. Acquired factor VII deficiency associated with pleural liposarcoma. Blood Coagul Fibrinolysis 1994; 5:833-836.
9. Biron C, Bengler C, Gris JC, Schved JF. Acquired isolated factor VII deficiency during sepsis. Haemostasia 1997; 27:51-56.
10. Brunod M, Chatot-Henry C, Mehdaoui H, Richer C, Fonteau C. Acquired anti-factor VII (proconvertin) inhibitor: hemorrhage and thrombosis. Thromb Haemost 1998; 79:1065-1066.
11. Muleo G, Santoro R, Iannaccaro PG, Papaleo P, Leo F. The use of recombinant activated factor VII in congenital and acquired factor VII deficiencies. Blood Coagul Fibrinolysis 1998; 9:389-390.
12. Okajima K, Ishii M, Life-threatening bleeding in a case of autoantibody-induced factor VII deficiency. Int J Hematol 1999; 69:129-132.
13. White B, Martin M, Kelleher S, Browne P, McCann SR, Smith OP. Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII deficiency. Br J Haematol 1999; 106:254-255.
14. Toor AA, Slungaard A, Hedner U, Weisdorf DJ, Key NS. Acquired factor VII deficiency in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2002; 29:403-408.
15. Aguilar C, Lucia JF, Hernandez P. A case of an inhibitor autoantibody to coagulation factor VII. Haemophilia 2003; 9:119-120.
16. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:612.
17. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73:247-251.
18. Kamikubo Y, Miyamoto S, Iwasa A, Ishii M, Okajima K. Purification and characterization of factor VII inhibitor found in a patient with life threatening bleeding. Thromb Haemost 2000; 83:60-64.
19. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000; 26:385-391.
20. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000; 26:425-432.
21. Nilsson IM, Hedner U. Characteristics of various factor VIII concentrates used in treatment of haemophilia A. Br J Haematol 1977; 37:543-557.
22. Prowse CV. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74:1191-1196.
23. Berrettini M, Mariani G, Schiavoni M, Rocino A, Di Paolantonio T, Longo G, et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica 2001; 86:640-645.